Shire looks for more ADHD mileage with new data on long-acting prospect


Shire’s long-delayed ADHD candidate has racked up more positive data in its quest to finally hit the market. And with FDA approval in sight, the drugmaker will have to find the space to compete.

The Dublin drugmaker announced last week that two dosage strengths of prospect SHP465 had beat a placebo in treating adult ADHD patients. Shire will add these results to a pile of 16 other SHP465 studies it intends to take to regulators, and it’s crossing its fingers for a green light to launch in the second half of 2017.

The company is hopeful it will, considering the positive Phase III data in pediatric patients reported back in April. The FDA requested that study in 2014 when it turned down SHP465, which is a long-acting version of Adderall XR.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Before that setback, Shire had predicted the drug--originally submitted to regulators in 2006--would bump up its share of the U.S. ADHD market to 5%. But now, it’ll be up to the company to carve out a place for the med amid rampant generic competition.

Shire has been looking to get as much mileage as possible out of its flagship ADHD franchise, and that goal has involved chasing after new indications, too. Not so long ago it snagged one for anchor drug Vyvanse in binge eating disorder, a label expansion that could add $200 million to $300 million to sales by 2020, or so CEO Flemming Ornskov has said. Ornskov also sees the potential for bigger peak sales down the line as awareness of the condition spreads.

At the same time, Shire has been looking to move beyond ADHD by throwing itself headfirst into the rare-disease field. It recently bolstered its position in that arena by swallowing Baxter's new spinoff Baxalta, a major player in the hemophilia space.

That’s not to say Shire wouldn’t like to keep churning out ADHD sales, and if its new candidate wins approval, the company will have the IP protection to do just that. If SHP465 gets the green light, it’ll net three years of Hatch-Waxman exclusivity, and it’ll have at least three patents with expiration dates as late as May of 2029, Shire said.

- read Shire's release 

Special Report: The 25 most influential people in biopharma in 2015 - Flemming Ornskov - Shire

Related Articles:
It’s good and bad news at Shire as it posts ADHD, premature infant trial updates
With Baxalta in hand, Shire's not looking to buy. But sell? Maybe​
Shire's binge-eating push on Vyvanse feeds Q1 earnings beat
Shire's ADHD star Vyvanse scores FDA's first binge eating approval

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.